AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16122956
Drug: Saline given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline given IV 120 min after oesophageal acid infusion
Trial: 15513550
Drug: Daily nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily nasal spray with physiological saline
Trial: 11176172
Drug: Normal monocytes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal monocytes incubated with septic serum and anti-IL-10 antibodies
Trial: 11176172
Drug: Normal monocytes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal monocytes incubated with anti-TGF-beta antibodies
Trial: 9316690
Drug: Flunarizine (FZ)
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine (FZ) 20 mg
Trial: 9316690
Drug: Cinnarizine (CZ)
RxNorm normalized name: cinnarizine
DrugBank: Cinnarizine (DB00568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine (CZ) 150 mg
Trial: 2898422
Drug: olsalazine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olsalazine 500 mg bd
Trial: 2898422
Drug: sulphasalazine 1
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sulphasalazine 1 g bd
Trial: 30780126
Drug: Diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and metformin therapy
Trial: 23737342
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with targeted arterial infusion of verapamil
Trial: 23737342
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with targeted arterial infusion of verapamil in patients with liver metastases
Trial: 17873673
Drug: Oxygenated glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygenated glycerol triester (OGT) oral spray (1 or 2 sprays up to 4 times daily)
Trial: 17873673
Drug: Oxygenated glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygenated glycerol triester (OGT) oral spray
Trial: 15689192
Drug: Sumatriptan nasal
RxNorm normalized name: SUMAtriptan nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan nasal spray administered 120 min after the onset of the attack
Trial: 9918893
Drug: Celiprolol 200
RxNorm normalized name: celiprolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol 200 mg daily
Trial: 2316840
Drug: Inhaled nebulisation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nebulisation using a jet nebuliser
Trial: 2316840
Drug: Cricothyroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cricothyroid injection
Trial: 7309300
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg dihydroxydibutylether (DHBE)
Trial: 17708159
Drug: Cold blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold blood cardioplegia solution with PA vent and PEEP during CPB
Trial: 12677762
Drug: Elastic compression
RxNorm normalized name: elastin
DrugBank: Elastin (human) (DB15364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elastic compression therapy (group B)
Trial: 21697300
Drug: High antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High antioxidant spice blend (14 g) added to a 5060‐kJ (1200 kcal) meal
Trial: 17085985
Drug: Statin drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin drugs for lowering cardiovascular risk
Trial: 8378854
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 125 mg/day and curantyl (150‐225 mg/day) from gestation week 12‐19 till delivery
Trial: 3005377
Drug: Ciprostene at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprostene at a maximum dose of 160 ng/kg/min for 8 hours daily for three days.
Trial: 29362248
Drug: Narrative medicine-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative medicine-based intervention (three 30 min talks with GPs over 12 months)
Trial: 29362248
Drug: Narrative medicine-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative medicine-based intervention
Trial: 26406216
Drug: PA lumbar
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PA lumbar mobilization plus traditional treatment (Ultrasonic and Infra-red)
Trial: 26406216
Drug: Placebo mobilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mobilization plus traditional treatment
Trial: 21413975
Drug: n-3 LC-PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 LC-PUFA supplements
Trial: 10551191
Drug: Regular telephone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular telephone contact with a diabetes nurse educator for advice about adjustment of insulin therapy
Trial: 1662671
Drug: Herpes simplex
RxNorm normalized name: herpes simplex 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herpes simplex type I subunit vaccine
Trial: 6133637
Drug: Prazosin, 14.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin, 14.0 +/- 2.4 mg/day in three equal doses
Trial: 26150543
Drug: Placebo arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm of a randomized clinical trial of Chinese medicine
Trial: 20222930
Drug: Cold atmospheric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold atmospheric argon plasma treatment (5 min daily) in addition to standard wound care
Trial: 12410058
Drug: Olanzapine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (up to 30 mg per day)
Trial: 12410058
Drug: Olanzapine (high-dose)
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine (high-dose)
Trial: 2496619
Drug: Flumazenil (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.3 mg)
Trial: 2496619
Drug: Midazolam-Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam-Ringer's solution
Trial: 901629
Drug: Hypolipidaemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypolipidaemic therapy
Trial: 29535259
Drug: High-frequency oscillating
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency oscillating device for respiratory muscle training (8 weeks, 3 times daily)
Trial: 26316701
Drug: Test ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test ondansetron oral soluble film formulation
Trial: 26316701
Drug: Reference ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference ondansetron oral soluble film formulation
Trial: 23852061
Drug: Nitrous oxide/oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrous oxide/oxygen inhalation sedation and local anesthesia
Trial: 18503607
Drug: Glyburide co-administered
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide co-administered with Sitagliptin
Trial: 14618045
Drug: Sotalol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (80 mg two times daily for five days starting from the morning of the first postoperative day)
Trial: 14618045
Drug: Magnesium (1.5
RxNorm normalized name: bicarb dialy soln 11 without K calcium (2.5 mEq/L)-magnesium (1.5 mEq/L) HEMODIALYS SOLUTION, NON-ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium (1.5 g daily for six days starting in the operating room just before cardiopulmonary bypass)
Trial: 3435920
Drug: Methotrexate (MTX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (MTX), 40 mg/m2 iv push weekly
Trial: 3435920
Drug: Sequential Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sequential Methotrexate and 5-fluorouracil (MTX 150 mg/m2 iv for 1 h; 5-FU 600 mg/m2 iv for 2 h; leucovorin rescue 10 mg/m2 iv and orally every 6 h 4 times, repeated every 10 days)
Trial: 25950425
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules and normal saline infusion perioperatively (control)
Trial: 25950425
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules and lidocaine 1 mg/kg intravenous bolus dose followed by 2 mg/kg/h infusion until skin closure
Trial: 25950425
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg oral pregabalin and normal saline infusion perioperatively
Trial: 25950425
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg oral pregabalin and lidocaine 2 mg/kg/h infusion until skin closure
Trial: 10570388
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream (dosed twice daily, once daily, and 3 times weekly)
Trial: 10570388
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream (dosed twice weekly)
Trial: 10570388
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream (dosed once weekly)
Trial: 8932457
Drug: Test suspensions
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test suspensions
Trial: 1881558
Drug: Picotamide (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picotamide (900 mg/die)
Trial: 7051249
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) 160 mg of TMP plus 800 mg of SMZ daily for four months
Trial: 31470971
Drug: Passive intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Passive intervention group (PG) - oral health-related information and activity record cards
Trial: 24340770
Drug: Medication based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication based on antlers of Siberian stags
Trial: 19833861
Drug: Laropiprant with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laropiprant with extended-release niacin
Trial: 19833861
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin alone
Trial: 15154607
Drug: 2.0 g
RxNorm normalized name: Fifty50 2.0 Glucose Meter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g daily GLA (borage oil)
Trial: 10631624
Drug: Doxazosin 2
RxNorm normalized name: doxazosin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 2 mg tablet
Trial: 9181630
Drug: Trazodone (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (50, 100 and 200 mg)
Trial: 9181630
Drug: Triazolam (0.125,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.125, 0.25, 0.50 mg)
Trial: 1373007
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline solution (7.5% NaCl)
Trial: 2857210
Drug: Hydrochlorothiazide 50
RxNorm normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 50 mg twice a day
Trial: 2857210
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hydrochlorothiazide and propranolol
Trial: 28515369
Drug: Aggressive lipid-
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive lipid- and blood pressure-lowering therapy
Trial: 18319412
Drug: Gemcitabine (30-minute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (30-minute infusion of 1000 mg/m2 once per week for 3 weeks prior to chemoradiation and for 12 weeks after chemoradiation)
Trial: 18319412
Drug: Fluorouracil (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil (continuous infusion of 250 mg/m2 per day for 3 weeks prior to chemoradiation and for 12 weeks after chemoradiation)
Trial: 16870074
Drug: 12 μg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 μg/h fentanyl transdermal system (fentanyl TTS)
Trial: 9050128
Drug: Neuroleptic doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptic doses
Trial: 3532010
Drug: Aerosolized metaproterenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized metaproterenol (second treatment)
Trial: 29860500
Drug: Intralipid/heparin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid/heparin infusion
Trial: 23969265
Drug: 100 kVp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 kVp protocol with 20% reduced contrast dose
Trial: 22107850
Drug: MenACWY‐TT and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY‐TT and HepA/B (Twinrix) co-administered
Trial: 10634681
Drug: Intensive prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive prevention (counseling, F‐varnish applications, F‐lozenges, sealants, chlorhexidine)
Trial: 360903
Drug: 5% ribavirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% ribavirin in ointment base
Trial: 31424713
Drug: Halobetasol 0.01%/Tazarotene
RxNorm normalized name: HALOBETASOL 0.01%/TAZAROTENE 0.045% LOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halobetasol 0.01%/Tazarotene 0.045% lotion (HP/TAZ)
Trial: 8466427
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (E) - vinyl urinary bags reused for 4 weeks with daily decontamination using dilute bleach rinse
Trial: 8466427
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C) - vinyl urinary bags replaced weekly
Trial: 3026052
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (40 mg orally four times daily)
Trial: 3026052
Drug: Tamoxifen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (10 mg orally twice daily)
Trial: 30734195
Drug: Pyloric injection
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyloric injection of magnesium sulfate-lidocaine mixture
Trial: 30734195
Drug: Pyloric injection
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyloric injection of normal saline (control)
Trial: 10075322
Drug: Partially defatted
RxNorm normalized name: rice bran, defatted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially defatted flaxseed (approximately 50 g partially defatted flaxseed/d)
Trial: 1898585
Drug: Mupirocin intranasally
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mupirocin intranasally twice daily for 5 days
Trial: 28279086
Drug: Financial incentives
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Financial incentives for medication compliance (0, 1, 2, or 3 incentives awarded quarterly over 1 year)
Trial: 25191766
Drug: alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-lipoic acid (LA) supplementation (500 mg/day) for three months
Trial: 22027944
Drug: Red ginseng
RxNorm normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red ginseng (3 g per day, including 60 mg of ginsenosides)
Trial: 20501928
Drug: Reports with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reports with spin focusing only on treatment effectiveness
Trial: 18520980
Drug: 200-mg retarded-release
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-mg retarded-release levodopa/carbidopa (LD/CD)
Trial: 18520980
Drug: 150-mg levodopa/carbidopa/entacapone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150-mg levodopa/carbidopa/entacapone (LD/CD/EN)
Trial: 1828336
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (2.04 g/d)
Trial: 1828336
Drug: safflower oil
RxNorm normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: safflower oil (4.8 g/d of linoleic acid)
Trial: 116282
Drug: Oxprenolol (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol (480 mg)
Trial: 30612727
Drug: Insulin-treated diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-treated diabetes mellitus (ITDM)
Trial: 30612727
Drug: Non-insulin treated
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-insulin treated diabetes mellitus (NITDM)
Trial: 17974868
Drug: Multicomponent behavioral
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent behavioral treatment (MBT)
Trial: 11666123
Drug: TTFCA (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTFCA (total triterpenic fraction of Centella asiatica), 60 mg twice daily for 6 weeks
Trial: 8053015
Drug: Intramuscular sulfadoxine‐pyrimethamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular sulfadoxine‐pyrimethamine
Trial: 29550012
Drug: No glide
RxNorm normalized name: Chamois Glide
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No glide path preparation
Trial: 24646034
Drug: Aerosolized antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized antibiotics (AA) given for 14 days or until extubation.
Trial: 16027801
Drug: Probucol 250
RxNorm normalized name: probucol 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol 250 mg/day for 7-10 days before and 6 months after angioplasty
Trial: 16027801
Drug: Probucol 250
RxNorm normalized name: probucol 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol 250 mg/day for 6 months after angioplasty
Trial: 16027801
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no probucol therapy)
Trial: 6346782
Drug: Cimethidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimethidine 400 mg intramuscularly as pre-anesthetic
Trial: 29121432
Drug: Alpine climate
RxNorm normalized name: Alpine strawberry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpine climate treatment (6-week personalized integrative multidisciplinary treatment in Switzerland)
Trial: 29121432
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment in moderate maritime climate (Netherlands)
Trial: 21636667
Drug: Fluticasone/Salmeterol combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/Salmeterol combination (FP/SM) 125/25 μg, two puffs bid for 2 weeks
Trial: 21636667
Drug: Fluticasone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone (250 μg), two puffs bid for 2 weeks
Trial: 21636667
Drug: Fluticasone/Salmeterol combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/Salmeterol combination (FP/SM)
Trial: 21636667
Drug: Fluticasone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone (250 μg)
Trial: 20237772
Drug: 900 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg/day OXC
Trial: 20237772
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day CBZ
Trial: 15196300
Drug: Valproate 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valproate 1000 mg
Trial: 11521982
Drug: Antibodies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies to H. pylori in Group A (S-PGI <25 microg/l) and Group C (S-PGI >100 microg/l)
Trial: 11521982
Drug: Antibodies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies to CagA in relation to S-PGI levels
Trial: 11521982
Drug: Antibodies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies to CagA in relation to severity of atrophic gastritis
Trial: 9475824
Drug: Zinc lozenges
RxNorm normalized name: Zinc Lozenges
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc lozenges (zinc gluconate)
Trial: 2501852
Drug: Au parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Au parenteral preparations
Trial: 2501852
Drug: D-penicillamine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-penicillamine (average daily dose of 450 mg)
Trial: 78625
Drug: Trioxsalen baths
RxNorm normalized name: Trioxsalen
DrugBank: Trioxsalen (DB04571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trioxsalen baths (0.5 mg/1) for 15 minutes followed by irradiation with dysprosium lamps (Osram HQI‐TS)
Trial: 78625
Drug: Methoxsalen bath
RxNorm normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methoxsalen bath (1 mg/l)
Trial: 25339740
Drug: DLPFC activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DLPFC activation during antisaccade preparation in ALS patients